间变性淋巴瘤激酶抑制剂的遴选量化评估  

Selection and quantitative evaluation of anaplastic lymphoma kinase inhibitors

作　　者：李萍 庄捷 孙红 冯彩萍 魏晓霞 蔡加琴 LI Ping;ZHUANG Jie;SUN Hong;FENG Caiping;WEI Xiaoria;CAI Jiaqin(Department of Pharmacy,Fuzhou University Affiliated Provincial Hospital,Fuzhou,Fujian 35000l,China)

机构地区：[1]福州大学附属省立医院药学部,福州350001

出　　处：《福建医药杂志》2025年第1期1-5,共5页Fujian Medical Journal

摘　　要：目的 通过对克唑替尼、塞瑞替尼、阿来替尼、布格替尼、恩沙替尼和洛拉替尼进行量化评估,为医疗机构遴选间变性淋巴瘤激酶抑制剂(ALK-TKIs)提供依据。方法 应用《中国医疗机构药品评价与遴选快速指南》的评价维度、评价细则及评价方法,对克唑替尼、塞瑞替尼、阿来替尼、布格替尼、恩沙替尼和洛拉替尼进行药品评价。结果 克唑替尼、塞瑞替尼、阿来替尼、布格替尼、恩沙替尼和洛拉替尼的遴选量化评估总分分别为79.12、80.50、79.99、82.00、70.14、79.31分。结论 根据评分结果,医疗机构在引入ALK-TKIs时,建议遴选的顺序依次为布格替尼、塞瑞替尼、阿来替尼、洛拉替尼、克唑替尼、恩沙替尼。Objective To perform quantitative evaluation for crizotinib,ceritinib,alectinib,brigatinib,ensartinib and lorlatinib,so as to provide a basis for selecting anaplastic lymphoma kinase inhibitors(ALK-TKIs)for medical institutions.Methods The drug evaluation of crizotinib,ceritinib,alectinib,brigatinib,ensartinib and lorlatinib was carried out by using the evaluation dimensions,evaluation rules and evaluation methods of the"Quick Guidelines for Drug Evaluation and Selection in Chinese Medical Institutions".Results The overall score of crizotinib,ceritinib,alectinib,brigatinib,ensartinib and loratinib was 79,12,80.50,79.99,82.00,70.14,79.31.Conclusion According to the score results,when introducing ALK-TKIs in medical institutions,the recommended selection order is brigatinib,ceritinib,alectinib,lorlatinib,crizotinib,and ensartinib.

关 键 词：克唑替尼 塞瑞替尼 阿来替尼 布格替尼 恩沙替尼 洛拉替尼 药品遴选 

分 类 号：R979.1[医药卫生—药品]